- Home
- GLP vs VRDN Comparison
GLP vs VRDN Comparison
Compare GLP & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLP
- VRDN
- Stock Information
- Founded
- GLP 2005
- VRDN 2006
- Country
- GLP United States
- VRDN United States
- Employees
- GLP N/A
- VRDN N/A
- Industry
- GLP Oil Refining/Marketing
- VRDN Medical Specialities
- Sector
- GLP Energy
- VRDN Health Care
- Exchange
- GLP Nasdaq
- VRDN Nasdaq
- Market Cap
- GLP 1.7B
- VRDN 1.6B
- IPO Year
- GLP 2005
- VRDN N/A
- Fundamental
- Price
- GLP $45.21
- VRDN $23.63
- Analyst Decision
- GLP Hold
- VRDN Strong Buy
- Analyst Count
- GLP 1
- VRDN 10
- Target Price
- GLP $56.00
- VRDN $36.78
- AVG Volume (30 Days)
- GLP 42.4K
- VRDN 1.5M
- Earning Date
- GLP 11-07-2025
- VRDN 11-13-2025
- Dividend Yield
- GLP 6.64%
- VRDN N/A
- EPS Growth
- GLP N/A
- VRDN N/A
- EPS
- GLP 2.60
- VRDN N/A
- Revenue
- GLP $17,827,598,000.00
- VRDN $305,000.00
- Revenue This Year
- GLP $37.98
- VRDN N/A
- Revenue Next Year
- GLP $28.27
- VRDN $34,044.63
- P/E Ratio
- GLP $17.39
- VRDN N/A
- Revenue Growth
- GLP 3.74
- VRDN 5.90
- 52 Week Low
- GLP $43.20
- VRDN $9.90
- 52 Week High
- GLP $60.00
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- GLP 40.42
- VRDN 62.01
- Support Level
- GLP $44.18
- VRDN $21.65
- Resistance Level
- GLP $46.37
- VRDN $24.23
- Average True Range (ATR)
- GLP 1.20
- VRDN 1.11
- MACD
- GLP 0.22
- VRDN -0.03
- Stochastic Oscillator
- GLP 62.09
- VRDN 68.07
About GLP Global Partners LP Common Units representing Limited Partner Interests
Global Partners LP is a limited partnership that acts as a midstream logistics and marketing company. It is mainly engaged in purchasing, selling, storing and logistics of transporting petroleum and related products. The company owns and operates and control terminal networks of refined petroleum products and renewable fuels in Massachusetts, Maine, Connecticut, Vermont, and other places. It distributes gasoline and gasoline blendstocks, distillates, residual oil, renewable fuels, crude oil, natural gas and propane to wholesalers, retailers and commercial customers. The company operates through three segments i.e. Wholesale, Gasoline Distribution and Station Operations and Commercial. It generates maximum revenue from the Wholesale segment.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).